Examining adjuvant radiation dose in head and neck squamous cell carcinoma.

Vladimir AvkshtolElizabeth A HandorfJohn A RidgeBrooke K LeachmanJeffrey C LiuJessica BaumanThomas J Galloway

Published in: Head & neck (2019)

There was no survival benefit from postoperative dose escalation above EQD2 60 Gy even in a high-risk cohort.

Keyphrases